MAPK3 and type 2 diabetes mellitus: The main findings of this study are the following: 1) Na2S therapy administered at the time of reperfusion reduces MI/R injury in the setting of T2DM; 2) Na2S therapy activates the Erk1/2 arm of the RISK pathway; 3) Erk1/2 signaling increases anti-apoptotic proteins and inhibits the activation of GSK3β 4) Na2S therapy provides it’s infarct sparing effects in an Erk1/2-dependent manner.